) and partner
) announced that data from a phase II study (n = 168) evaluating
the use of brodalumab in patients suffering from psoriatic
arthritis was published in The New England Journal of Medicine
(NEJM). The data will also be presented at the annual meeting of
the European League Against Rheumatism (EULAR).
In the randomized, double-blind, placebo-controlled, phase II
study, brodalumab demonstrated significant improvement (measured
using the American College of Rheumatology score of 20%
improvement/ACR20) in signs and clinical symptoms associated with
psoriatic arthritis including tender and swollen joints at 12
weeks. It was also found that several patients continued to improve
and the improvement was sustained through the first 52 weeks of the
Amgen and AstraZeneca are currently conducting two phase III
studies (AMVISION-1 and AMVISION-2) evaluating the use of
brodalumab in patients suffering from psoriatic arthritis. The
study will also assess brodalumab's ability to prevent joint
Apart from psoriatic arthritis, the companies are evaluating
brodalumab for moderate-to-severe plaque psoriasis (phase III) and
asthma (phase II).
Both Amgen and AstraZeneca are working on strengthening their
product portfolio and brodalumab is one of the key candidates in
their pipeline. According to a press release issued by AstraZeneca,
analysts estimate peak sales of brodalumab to range between $0.5
billion and $1.5 billion.
Amgen and AstraZeneca are both Zacks Rank #3 (Hold) stocks. Some
better-ranked stocks in the health care sector include
). Both Gilead and Allergan are Zacks Rank #1 (Strong Buy)
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
AMGEN INC (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.